Phase I study evaluating high dose ADXS11-001 treatment in women with carcinoma of the cervix.

被引：0
|
作者：
Ghamande, Sharad A.
Dobbins, Robin
Marshall, Lisa
Wheatley, Donna
Prince, Cheryl
Mauro, David J.
Janik, John Edward
Khleif, Samir
机构：
[1] Georgia Regents Univ, Augusta, GA USA
[2] Georgia Reagents Univ, GRU Canc Ctr, Augusta, GA USA
[3] Advaxis Inc, Princeton, NJ USA
[4] Georgia Hlth Sci Univ, Ctr Canc, North Augusta, GA USA
[5] Georgia Regents Univ, Ctr Canc, Augusta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.tps3096
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3096
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma
    Monk, Paul
    Lam, Elaine
    Mortazavi, Amir
    Kendra, Kari
    Lesinski, Gregory B.
    Mace, Thomas A.
    Geyer, Susan
    Carson, William E., III
    Tahiri, Sanaa
    Bhinder, Arvinder
    Clinton, Steven K.
    Olencki, Thomas
    JOURNAL OF IMMUNOTHERAPY, 2014, 37 (03) : 180 - 186
  • [42] A phase II trial of 5-fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: A gynecologic oncology group study
    Look, KY
    Blessing, JA
    Gallup, DG
    Lentz, SS
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (05): : 439 - 441
  • [43] A phase I/II study of high-dose cytarabine and topotecan for the treatment of resistant acute myelogenous leukemia.
    Schiller, G
    Hepner, A
    Lee, M
    Sawyers, C
    Paquette, R
    Territo, M
    BLOOD, 1998, 92 (10) : 218B - 218B
  • [44] Phase I study of high dose etoposide phosphatase with filgrastim (G-CSF) in the treatment of advanced refractory malignancies
    John D. Hainsworth
    Susan M. Utley
    F. Anthony Greco
    Investigational New Drugs, 1997, 15 : 325 - 329
  • [45] Phase I study of high dose etoposide phosphatase with filgrastim (G-CSF) in the treatment of advanced refractory malignancies
    Hainsworth, JD
    Utley, SM
    Greco, FA
    INVESTIGATIONAL NEW DRUGS, 1997, 15 (04) : 325 - 329
  • [46] Phase I dose-escalation study of docetaxel, CPT-11 and cisplatin as first-line therapy in patients with advanced gastric carcinoma: a feasible triplet with high activity
    Salazar, Ramon
    Font, Albert
    Maurel, Joan
    Casado, Esther
    Taron, Miquel
    Gallego, Rosa
    Tabernero, Joseph
    Manos, Laura
    Luis Tisaire, Jose
    Abad, Albert
    ANNALS OF ONCOLOGY, 2004, 15 : 236 - 236
  • [47] A Phase I study of high-dose-rate intraluminal brachytherapy as palliative treatment in extrahepatic biliary tract cancer
    Mattiucci, Gian Carlo
    Autorino, Rosa
    Tringali, Andrea
    Perri, Vincenzo
    Balducci, Mario
    Deodato, Francesco
    Gambacorta, Maria Antonietta
    Mantini, Giovanna
    Tagliaferri, Luca
    Mutignani, Massimiliano
    Morganti, Alessio. Giuseppe
    BRACHYTHERAPY, 2015, 14 (03) : 401 - 404
  • [48] Results of the phase I "Lumed " study: Dose escalation of 177Lu-PP-F11N in patients with medullary thyroid carcinoma.
    Rottenburger, C.
    Hentschel, M.
    McDougall, L.
    Kaul, F.
    Mansi, R.
    Fani, M.
    Vija, H. A.
    Schibli, R.
    Geistlich, S.
    Behe, M.
    Christ, E. R.
    Wild, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S202 - S202
  • [49] CF102 for the treatment of hepatocellular carcinoma: A phase I/II, open-label, dose-escalation study.
    Stemmer, Salomon M.
    Benjaminov, Ofer
    Medalia, Gal
    Ciuraru, Noa
    Silverman, Michael H.
    Bar Yehuda, Sara
    Fishman, Sari
    Harpaz, Zivit
    Farbstein, Motti
    Cohen, Shira
    Petoka, Renana
    Singer, Barak
    Kerns, William D.
    Fishman, Pnina
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] PHASE-II STUDY OF HIGH-DOSE MITOXANTRONE IN THE TREATMENT OF RECURRENT SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
    STEWART, DJ
    CRIPPS, C
    MAROUN, JA
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1987, 10 (04): : 307 - 309
12345